Sort
82,697 grants matching “vaccine development”
Core B - MappBiopharmaceutical, Inc.
$800,065Larry Zeitlin · Henry M. Jackson Fdn For The Adv Mil/Med · U19 · FY2020 · AI
Defining functional humoral correlates of immunity to guide vaccine design
$800,065Facundo Damian Batista · Massachusetts General Hospital · R01 · FY2022 · AI
Defining the impact of host factors on the molecular architecture and bacterial physiology of Staphylococcus aureus abscesses
$800,040James E Cassat · Vanderbilt University Medical Center · R01 · FY2020 · AI
Pragmatic Implementation Science Approaches to Assess and Enhance Value of Cancer Prevention and Control in Rural Primary Care
$800,039Russell E Glasgow · University Of Colorado Denver · P50 · FY2019 · CA
Development Of Vaccines For Genital Herpes Simplex Infection
$800,033Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Epstein-Barr Virus Associated Disorders
$800,033Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
RECENT OUTBREAKS OF BIRD FLU (H5N1) IN U.S. CATTLE HAVE RAISED CONCERNS ABOUT HOW FLU VIRUSES SPREAD IN LIVESTOCK. HOWEVER, ANOTHER LESSER-KNOWN VIRUS, INFLUENZA D (IDV), IS ALREADY PRESENT IN CATTLE WORLDWIDE AND EVOLVING RAPIDLY. WHILE IDV WAS INITIALLY THOUGHT TO CAUSE ONLY MILD ILLNESS, NEWER STRAINS ARE NOW LEADING TO SERIOUS RESPIRATORY DISEASE IN CALVES. EVEN MORE CONCERNING, IDV CAN INFECT OTHER FARM ANIMALS AND EVEN HUMANS, POSING A BROADER RISK TO AGRICULTURE AND PUBLIC HEALTH.CURRENTLY, THERE ARE NO RELIABLE ANTIBODY DETECTION TESTS TO TRACK THE EXPOSURE OF CATTLE TO IDV AND NO VACCINES TO PROTECT CATTLE, LEAVING THE LIVESTOCK INDUSTRY VULNERABLE. WITHOUT ACTION, IDV COULD BECOME A SIGNIFICANT THREAT TO CATTLE HEALTH, FARMERS' LIVELIHOODS, AND THE STABILITY OF U.S. AGRICULTURE.TO ADDRESS THIS, EXPERTS, THE TEAM LED BY THE UNIVERSITY OF PITTSBURGH IN COLLABORATION WITH SCIENTISTS FROM SOUTH DAKOTA STATE UNIVERSITY ARE WORKING TOGETHER ON TWO CRITICAL SOLUTIONS. FIRST, WE ARE DEVELOPING NEW DIAGNOSTIC TESTS TO MONITOR IDV IN CATTLE AND OTHER LIVESTOCK. SECOND, WE ARE DEVELOPING AN INNOVATIVE NASAL SPRAY VACCINE TO PROTECT CATTLE FROM IDV AND PREVENT THE DISEASE FROM SPREADING.BY PROACTIVELY DEVELOPING BETTER MONITORING TOOLS AND A VACCINE, THIS RESEARCH WILL HELP SAFEGUARD CATTLE, SUPPORT US CATTLE INDUSTRY, AND STRENGTHEN THE SUSTAINABILITY AND PROFITABILITY OF THE U.S. LIVESTOCK INDUSTRY.
$800,000University Of Pittsburgh - Of The Commonwealth System Of Higher Education · · FY2025 · National Institute of Food and Agriculture
Integrative Omics of HepB Vaccine Response in Co-Infection with Parasites
$800,000Elias K Haddad · Drexel University · U19 · FY2017 · AI
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AFRICAN SWINE FEVER (ASF) IS A FOREIGN ANIMAL DISEASE, WHICH IS WIDESPREAD IN EUROPE AND ASIA, AND REMAINS ONE OF THE LARGEST THREATS TO PORK PRODUCTION WORLDWIDE. TO DATE, THERE ARE NO VACCINES OR TREATMENTS ON THE MARKET, AND THE ONLY WAY TO CONTROL ASF IS TO KILL INFECTED ANIMALS AND, SOMETIMES, THE ENTIRE HERD FROM WHICH THEY CAME. THE ASF PANDEMIC RECENTLY REACHED THE ISLAND OF HISPANIOLA, ON THE U.S. DOORSTEP, INCREASING THE RISK OF ASF REACHING U.S. SOIL.AN ASF OUTBREAK IN THE U.S. WOULD HAVE AN ESTIMATED IMPACT OF $15-50 BILLION IN LOSSES FROM PORK PRODUCTS, EXPORT MARKETS, JOBS, AND RECOVERY COSTS. THERE IS A HIGH PRIORITY TO DEVELOP ASF VACCINES AND DIAGNOSTIC TOOLS TO REDUCE THE ASF THREAT TO THE U.S. AN ASF VACCINE DEVELOPED AT THE USDA (ASFV-G-DELTA-I177L) IS CURRENTLY BEING TESTED IN VIETNAM AND MAY END UP ON THE GLOBAL MARKET. HOWEVER, ASF VACCINATED ANIMALS CANNOT BE DIAGNOSED BY STANDARD ASF TESTS; RATHER, A TEST THAT CAN DIFFERENTIATE INFECTED FROM VACCINATED ANIMALS(DIVA TEST) IS NECESSARY TO AVOID MISDIAGNOSING VACCINATED ANIMALS. OUR PROJECT GOALS ARE TO DEVELOP THIS CRITICAL ASF DIVA TEST AND DEVELOP TOOLS FOR ASF RESEARCH. OUR OBJECTIVES INCLUDE DEVELOPING AND VALIDATING TWO IMMUNOASSAYS, BASED ON AN ENZYME LINKED IMMUNO-SORBENT ASSAY (ELISA) PLATFORM, AND DEVELOPING ASF MONOCLONAL ANTIBODIES THAT CAN BE USED TO STUDY THE ASF VIRUS. WE PREVIOUSLY INITIATED DEVELOPMENT OF ASF ELISAS AND ANTIBODIES WITH A SMALL BUSINESS INNOVATIVE RESEARCH (SBIR I) GRANT FROM THE USDA. HOWEVER, OUR SBIR RESEARCH ONLY ESTABLISHED PROOF-OF-CONCEPT WORK AND FIRST-GENERATION RESEARCH TOOLS. THIS PROJECT WILL EXTEND BEYOND PREVIOUS WORK IN ORDER TO FURTHER DEVELOP, OPTIMIZE, AND VALIDATE THESE TOOLS FOR USE IN COMMERCIAL AND RESEARCH SETTINGS. THE COMMERCIALLY AVAILABLE DIAGNOSTIC TOOLS CAN HAVE A SIGNIFICANT IMPACT ON THE PORK INDUSTRY AND U.S. BIOSECURITY BY IMPROVING ASF DISEASE MANAGEMENT, AND THE ASF ANTIBODIES CAN SIGNIFICANTLY IMPROVE ASF DISEASE AND VIRUS RESEARCH.WE HAVE PROPOSED NEW RESEARCH STRATEGIES TO GO BEYOND OUR PREVIOUS WORK, INCLUDING USE OF ALTERNATIVE LABORATORY METHODS TO PRODUCE AND PURIFY ASF PROTEINS, WHICH ARE USED IN ELISA AND ANTIBODY DEVELOPMENT. WE WILL DEVELOP NEW FORMULATIONS THAT AFFECT ELISA BIOCHEMISTRY AND IMPACT DIAGNOSTIC PERFORMANCE, AND WE WILL DEVELOP AN ADDITIONAL ASSAY FORMAT CALLED A BLOCKING ELISA (BELISA). WE HAVE EXPANDED OUR MULTI-REGIONAL NETWORK FOR THIS PROJECT, WHICH WILL SUPPORT EXTENSIVE ELISA VALIDATION IN ACADEMIC, GOVERNMENT, AND BIOSECURITY LABORATORIES IN NORTH AMERICA, EUROPE, ASIA, AND AFRICA. THROUGH OUR NETWORK, WE WILL EVALUATE OVER 5000 SAMPLES WITH OUR ASF DIVA TEST. THIS WILL PROVIDE VALIDATION OF DIAGNOSTIC PERFORMANCE TO SUPPORT COMMERCIALIZATION OF THE DIVA TEST. WE WILL ALSO DISTRIBUTE ASF ANTIBODIES TO FOUR COLLABORATING LABS THAT WILL CONDUCT BASIC ASF RESEARCH AND EVALUATE DIFFERENT RESEARCH APPLICATIONS FOR THE ASF ANTIBODIES. THE RESULTS OF THEIR STUDIES WILL REFLECT THE,PRACTICAL USES FOR ASF ANTIBODIES, WHICH CAN BE DISSEMINATED TO THE BROADER ASF RESEARCH COMMUNITY.
$800,000Biostone Animal Health, Llc · · FY2023 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ANAPLASMA MARGINALEIS AN INTRAERYTHROCYTIC RICKETTSIAL PATHOGEN AND CAUSES THE MOST PREVALENT TICK-BORNE INFECTION OF CATTLE BOTH WORLDWIDE AND WITHIN THE U.S. IN THE U.S., THE MAJOR IMPACT IS EPISODIC OUTBREAKS IN WHICH MORBIDITY IS DUE TO SEVERE ANEMIA AND THE MEAN CASE FATALITY RATE HAS BEEN REPORTED AT 36%. ECONOMIC LOSSES DUE TO ANAPLASMOSIS ARE ESTIMATED AT ~$300 MILLION/YEAR. THERE ARE NO VACCINES CURRENTLY LICENSED IN THE U.S. THOSE USED ELSEWHERE CARRY THE RISK OF TRANSMITTING EMERGING PATHOGENS AND RELY ON THE COLD CHAIN. OUTER MEMBRANE PROTEIN (OMP) PREPARATIONS AND OMP COMPLEXES HAVE BEEN SHOWN TO INDUCE ROBUST PROTECTION. HOWEVER, THESE VACCINATION REGIMES REQUIRE TECHNICAL EXPERTISE, A COLD CHAIN, AND ARE NOT PRACTICAL FOR LARGE SCALE PRODUCTION. WE PROPOSE TO DEVELOP A VACCINE AGAINST ANAPLASMOSIS BASED ON THE OMP PREPARATIONS/COMPLEXES. WE WILL TEST THE HYPOTHESIS THAT THE PROTECTIVE CAPACITY OF OMP PREPARATIONS/COMPLEXES CAN BE RECAPITULATED WITH A DEFINED SET OF VACCINE CANDIDATES KNOWN TO BE PRESENT IN THE OMP PREPARATIONS. WE WILL DELIVER A COCKTAIL OF VACCINE CANDIDATES AS A GENETIC (OR DNA) VACCINE USING A GENE GUN. THIS PLATFORM CAN DELIVER AS MANY CANDIDATES AS NEEDED AND DOES NOT RELY ON A COLD CHAIN. WE WILL EMPLOY TICK CHALLENGES TO ENSURE RIGOROUS TESTING OF OUR VACCINE. THE PROJECT WILL INCORPORATE HOMOLOGOUS, HETEROLOGOUS AND FIELD CHALLENGE SCENARIOS. WE WILL TEST WHETHER WE CAN REDUCE THE NUMBER OF IMMUNOGENS IN THE VACCINE WITHOUT LOSING EFFICACY, AND WHETHER A VACCINE BASED ON US VARIANTS WILL PROVIDE PROTECTION IN A GLOBAL CONTEXT.
$800,000Washington State University · · FY2024 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** DISEASES OF SWINE ARE CAUSED BY THE PRRS VIRUS (PRRSV). PRRSV CONTINUES TO DISTRESS THE GLOBAL PORK INDUSTRY BY CAUSING ECONOMIC LOSSES ESTIMATED AT $664 MILLION EVERY YEAR DUE TO REPRODUCTIVE FAILURE, FATAL RESPIRATORY DISEASE, AND SUBSEQUENT SECONDARY BACTERIAL INFECTION.SWINE INFLUENZA VIRUS (SIV) CAUSES ACUTE RESPIRATORY DISEASES IN BREEDING AND NURSERY PIGS AND CAN PREDISPOSE THE INFECTED ANIMALS TO SECONDARY VIRAL AND BACTERIAL INFECTIONS. IN ADDITION TO THE ADVERSE ECONOMIC IMPACT ON PIG PRODUCERS, SIV IS ALSO A ZOONOTIC PATHOGEN DETRIMENTAL TO HUMANS. COINFECTIONOF PIGS WITH PRRSV, PORCINE CIRCOVIRUS TYPE 2 (PCV2), AND SIV ON THE SAME FARMS ALSO PLAYS A CRITICAL ROLE IN THE PORCINE RESPIRATORY DISEASE COMPLEX AND IS FREQUENTLY REPORTED.SINCE THE LATE 1990S, KILLED AND MODIFIED LIVE VIRUS (MLV) PRRSV VACCINES BASED ON ATTENUATED EUROPEAN OR NORTH AMERICAN PRRSV STRAINS HAVE BEEN COMMERCIALIZED AND USED TO CONTROL PRRS. THE MLV-PRRS VACCINE HAS SAFETY ISSUES DUE TO THE PERSISTENCE OF THE VACCINE VIRUS IN THE HOST AND INCREASED MUTATION RATES. CONSEQUENTLY, VACCINE-LIKE VIRULENT PRRSV STRAINS HAVE EMERGED AND CAUSED VACCINE FAILURES INSTEAD OF PROTECTING THE PIGS. LIKEWISE, CURRENTLY AVAILABLE INACTIVATED SWINE INFLUENZA VACCINES ARE INEFFECTIVE IN CONTROLLING SIV IN PIGS DUE TO THE STRAIN VARIABILITY.PREVIOUSLY, WE DEVELOPED A QUADRUPLE GENE-DELETED PSEUDORABIES VIRUS (PRVQMV) VACCINE VECTOR PLATFORM IN WHICH ENVELOPE GLYCOPROTEIN GE, US9, GG, AND THYMIDINE KINASE (TK) GENES ARE DELETED. A CHIMERIC PCV2 CAPSID PROTEIN (CAP) WAS ALSO INSERTED, RESULTING IN THE PRVQMV-CAP.IN THIS PROJECT, OUR GOALS ARE TO ENGINEER THE PRVQMV FURTHER, I) TO INCORPORATE THE PRSSV ENVELOPE PROTEINS GLYCOPROTEINS (GP2.GP3,GP4, AND GP5) AND THE MATRIX PROTEIN, AND TEST ITS VACCINE PROTECTIVE EFFICACY AGAINST A VIRULENT PRRSV CHALLENGE STRAIN AND II) TO INCORPORATE THE SIV ENVELOPE GLYCOPROTEINS H1N1 AND H3N2, AND TEST ITS PROTECTIVE EFFICACY AGAINST THE TWO DIFFERENT (H1N1 AND H3N2 STRAINS) VIRULENT INFLUENZA CHALLENGE VIRUSES.
$800,000Louisiana State University · · FY2024 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AVIAN INFLUENZA (AI) IS AMONG THE MOST ECONOMICALLY IMPORTANT DISEASES AFFECTING POULTRY AND POSES A SIGNIFICANT THREAT TO THE SUSTAINABILITY OF THE POULTRY INDUSTRY WORLDWIDE. OVER THE PAST TWO DECADES, OUTBREAKS OF AI, ESPECIALLY INVOLVING HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI), HAVE CAUSED SEVERE ECONOMIC LOSSES IN MANY COUNTRIES, INCLUDING THE UNITED STATES (U.S.). NOTABLY, THE SPREAD OF HPAI IN THE U.S. IN 2014-2015 AFFECTED 50 MILLION DOMESTIC BIRDS AND RESULTED IN AN ESTIMATED LOSS OF $3.3 BILLION. CURRENTLY, THE U.S. HAS BEEN FACING ANOTHER DEVASTATING OUTBREAK OF HPAI THAT BEGAN IN 2022 AND AS OF AUGUST 3, 2023 HAS AFFECTED 58.7 MILLION BIRDS IN 47 STATES, SURPASSING THE PREVIOUS RECORD OF 2014-2015 OUTBREAKAND STANDING OUT AS THE MOST SIGNIFICANT ANIMAL DISEASE EVENT IN THE HISTORY OF THE U.S.VACCINATION IS THE MOST COST-EFFECTIVE AND HUMANE METHOD FOR THE CONTROL AND PREVENTION OF VIRAL DISEASES IN LIVESTOCK AND POULTRY. HOWEVER, VIRUSES LIKE AVIAN INFLUENZA VIRUS (AIV), WHICH ARE CONSTANTLY MUTATING, REQUIRE VACCINE PLATFORM(S) THAT CAN BE RAPIDLY DEVELOPED AND DEPLOYED IN RESPONSE TO EMERGING STRAINS. THUS, FLEXIBLE VACCINE PLATFORMS THAT ENABLE RAPID UPDATES ON AIV ANTIGENS TO MATCH CIRCULATING VIRUSES IN ENDEMIC AREAS OR NEWLY EMERGING VIRUSES IN NON-ENDEMIC COUNTRIES ARE NEEDED. WE WILL TACKLE THIS PROBLEMS BY DEVELOPING NOVEL VACCINE DELIVERY PLATFORMS FOR HPAI BASED ON A NEW CONDORPOX VIRUS VECTOR AND ON A SELF-AMPLIFYING RNA TECHNOLOGY PLATFORM. ADDITIONALLY, WE WILL ALSO DEVELOP SEROLOGICAL ASSAYS THAT WILL ENABLE DIFFERENTIATION OF VACCINATED FROM INFECTED ANIMALS. THE OUTCOMES OF THE PROPOSED PROJECT WILL HAVE A SIGNIFICANT IMPACT ON ANIMAL HEALTH AND ON THE SUSTAINABILITY OF THE POULTRY INDUSTRY WORLDWIDE.
$800,000Cornell University · · FY2024 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** AFRICAN SWINE FEVER (ASF) IS AN ACUTE VIRAL DISEASE OF DOMESTIC SWINE WITH MORTALITY RATES APPROACHING 100%. CURRENTLY ENDEMIC IN EXTENSIVE REGIONS OF EURASIA, ASF IS OUT OF AFRICA FOREVER, A SITUATION THAT POSES A GRAVE THREAT TO THE US SWINE INDUSTRY. WHILE OUR CURRENT CONCERN IS ASFV GEORGIA-07, OTHER EMERGING ASFV STRAINS FROM AFRICAN RESERVOIRS THREATEN SWINE POPULATIONS FOR THE INDEFINITE FUTURE. ECONOMIC ANALYSIS INDICATES AN ASF OUTBREAK IN THE U.S. WOULD RESULT IN APPROXIMATELY $15 BILLION USD IN LOSSES, ASSUMING THE DISEASE IS RAPIDLY CONTROLLED.THERE IS NO VACCINE FOR ASF AVAILABLE. ALTHOUGH LIVE ATTENUATED VACCINES CURRENTLY UNDER DEVELOPMENT MIGHT BE HELPFUL IN ENDEMIC REGIONS,IT IS HARD TO IMAGINE A SCENARIO WHERE THEY WOULD BE SUITABLE FOR USE IN COUNTRIES WITH HIGHLY DEVELOPED SWINE INDUSTRIES LIKE THE U.S.; ISSUES OF EFFICACY, RESIDUAL PATHOGENICITY WITH IMMUNOPATHOLOGIC SEQUELAE, AND POTENTIAL FOR LONG-TERM VIRAL PERSISTENCE RAISE SIGNIFICANT SAFETYCONCERNS). EFFICACIOUS SUBUNIT/VECTORED ASF VACCINES WITH SIGNIFICANTLY ENHANCED SAFETY PROFILES ARE NEEDED FOR USE IN THE US.HERE, WE WILL: 1) EVALUATE PROTECTIVE EFFICACY OF ORF VIRUS AND PSEUDORABIES VIRUS VECTORS-EXPRESSING ASFV PROTECTICE ANTIGENS (PA) OF EPIDEMIC STRAIN GEORGIA-07 USING VACCINATION CHALLENGE EXPERIMENTS IN PIGS AND 2) IDENTIFY PA EPITOPES AND HOST RESPONSES ASSOCIATED WITH PROTECTION. PROJECT SUCCESS WILL PROVIDE CRITICAL FOUNDATIONAL INFORMATION NECESSARY FOR DESIGN/DEVELOPMENT OF SAFE AND EFFICACIOUS DIFFERENTIATE INFECTED FROM VACCINATED ANIMAL(DIVA) COMPATIBLE SUBUNIT OR VECTORED ASF VACCINES THAT WOULD BE OF CONSIDERABLE VALUE FOR EMERGENCY USE IN THE US SHOULD ASF BE INTRODUCED.
$800,000University Of Illinois · · FY2023 · National Institute of Food and Agriculture
** AWARDS ISSUED PRIOR TO JANUARY 20, 2025, WERE FUNDED UNDER PREVIOUS ADMINISTRATIONS AND MAY NOT REFLECT THE PRIORITIES AND POLICIES OF THE CURRENT ADMINISTRATION.** ACCORDING TO THE 2021 US AGRICULTURE STATISTICS, THE COMBINED VALUE OF PRODUCTION AND SALES FROM BROILERS, EGGS, TURKEYS, AND CHICKS WAS $46.1 BILLION. UNFORTUNATELY, AVAILABLE VACCINES DO NOT PROVIDE SUFFICIENT PROTECTION AGAINST EMERGING AND TRANSBOUNDARY INFECTIONS SUCH AS HIGHLY PATHOGENIC AVIAN INFLUENZA (HPAI) THAT IMPACTED THE POULTRY INDUSTRY EARLIER IN 2022. WE HYPOTHESIZE THAT DNA-BASED NANOPARTICLE VACCINES (NANOVACCINES) WILL IMPROVE EFFICIENCY AND DELIVERY OF ANTIGENS FOR ROBUST INDUCTION OF PROTECTIVE IMMUNITY AGAINST POULTRY PATHOGENS. RECENTLY, REPORTS FROM OUR GROUP INDICATED THAT A NOVEL NANOADJUVANT SYSTEM (TERMED QAC FOR QUIL-A-TREATED CHITOSAN) COMBINED WITH PLASMID DNA CONSTRUCTS WERE ABLE TO DELIVER VIRAL ANTIGENS AND MOUNT A STRONG, PROTECTIVE IMMUNITY IN CHICKENS AGAINST INFECTIOUS BRONCHITIS VIRUS (IBV). IN THIS PROJECT, WE WILL CAPITALIZE ON OUR EXPERIENCE IN DEVELOPING MOSAIC NANOVACCINES THAT CAN REPRESENT THOUSANDS OF CIRCULATING VIRAL ISOLATES. SPECIFICALLY, WE PLAN TO: FIRST, EXAMINE THE DELIVERY AND STABILITY OF AVIAN INFLUENZA-HEMAGGLUTININ (HA) ANTIGEN. WE WILL UTILIZE VACCINE CONSTRUCTS TO CHARACTERIZE MOSAIC ANTIGEN RELEASE KINETICS AND INFECTIVITY TO CHICKEN CELLS FOLLOWING DIFFERENT TEMPERATURE CONDITIONS THAT MIMIC FIELD APPLICATION. SECOND, WE WILL ANALYZE THE IMMUNOGENICITY OF SEVERAL VACCINE CONSTRUCTS IN CHICKENS USING INTRANASAL AND ORAL ROUTES. FINALLY, WE WILL ANALYZE THE OVERAL VACCINE PROTECTION BY FOLLOWING CHALLENGE WITH LPAI AND HPAI. OVERALL, DEVELOPING EFFECTIVE, SAFE, AND EASY TO ADMINISTER NANOVACCINES WILL SIGNIFICANTLY IMPROVE OUR PREPARATION TO CONTROL EMERGING AND RE-EMERGING INFECTIONS IN POULTRY AND OTHER ANIMALS.
$800,000University Of Wisconsin System · · FY2023 · National Institute of Food and Agriculture
Adjuvant Comparison and Characterization
$800,000Philip Felgner · University Of California-Irvine · N01 · FY2024 · AI
Advancing Vaccine adjuvant Research for Tuberculosis (TB)
$800,000Warwick Britton · University Of Sydney · N01 · FY2024 · AI
Nanomedicine development center for mechanobiology
$800,000Michael L Dustin · New York University School Of Medicine · PN2 · FY2013 · EY
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$800,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2017 · IP
Mandatory_Estimates of Vaccine Effectiveness Against Medically-Attended, PCR-Confirmed Influenza in West South Central U.S.
$800,000Manjusha Gaglani · Scott And White Memorial Hospital · U01 · FY2016 · IP
Adjuvant Comparison and Characterization in Influenza , Chlamydia muridarum, and Coxiella burnetii Vaccines
$800,000Philip Felgner · University Of California-Irvine · N01 · FY2023 · AI
Site Development for Emerging Diseases and Biodefense
$800,000National Institute Of Allergy And Infectious Diseases · Y01 · FY2011 · AI
Detrimental Effects of B-Cell-Th17 Axis in Antiviral Immunity in Smokers.
$799,998Farrah Kheradmand · Baylor College Of Medicine · R01 · FY2025 · HL
US Influenza Vaccine Effectiveness Network
$799,995Arnold S Monto · University Of Michigan At Ann Arbor · U01 · FY2019 · IP
Novel heterologous listeria-adenovirus mucosal vaccine for HIV-1
$799,977Fred Robert Frankel · University Of Pennsylvania · R56 · FY2009 · AI
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$799,976Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA